Jyoti Mehra - Gilead Sciences Executive Resources
| 0QYQ Stock | 90.22 0.27 0.30% |
Executive
Jyoti Mehra is Executive Resources of Gilead Sciences
| Age | 48 |
| Address | 333 Lakeside Drive, Foster City, CA, United States, 94404 |
| Phone | 650 574 3000 |
| Web | https://www.gilead.com |
Gilead Sciences Management Efficiency
The company has return on total asset (ROA) of 0.1196 % which means that it generated a profit of $0.1196 on every $100 spent on assets. This is way below average. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Total Current Assets is likely to gain to about 19.1 B in 2024, whereas Total Assets are likely to drop slightly above 73 B in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ian Ince | Playtech Plc | N/A | |
| James Bruno | United States Steel | 58 | |
| Steffen Latussek | Playtech Plc | N/A | |
| Tara Carraro | United States Steel | N/A | |
| CFA Price | Allianz Technology Trust | N/A | |
| Gary Vallerius | Zanaga Iron Ore | N/A | |
| Colin Ross | Ashtead Technology Holdings | N/A | |
| Carol Smith | AIM ImmunoTech | 73 | |
| Karen Zammit | Playtech Plc | N/A | |
| Christine CPM | United States Steel | 68 | |
| Kenneth Jaycox | United States Steel | 55 | |
| John Gordon | United States Steel | N/A | |
| Sabine Macaya | CleanTech Lithium plc | N/A | |
| Ralph Cavalli | AIM ImmunoTech | 66 | |
| Scott Buckiso | United States Steel | 57 | |
| Guillermo Trujillo | CleanTech Lithium plc | N/A | |
| Martin Knauth | Zanaga Iron Ore | N/A | |
| Steve Bugajski | United States Steel | N/A | |
| Price CFA | Allianz Technology Trust | N/A | |
| Marcelino Garay | CleanTech Lithium plc | N/A | |
| Michael Lindsell | Allianz Technology Trust | 63 | |
Management Performance
| Return On Equity | 0.0056 | ||||
| Return On Asset | 0.12 |
Gilead Sciences Leadership Team
Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Johanna Mercier, Chief Officer | ||
| Jyoti Mehra, Executive Resources | ||
| Andrew Dickinson, Executive CFO | ||
| Michael Quigley, VP Biology | ||
| Linda Higgins, Innovation Research | ||
| Daniel ODay, Chairman CEO | ||
| Deborah Telman, General Affairs | ||
| Deborah JD, General Affairs | ||
| Jacquie CFA, Vice Relations | ||
| Diane Wilfong, Corp VP | ||
| Flavius MD, Executive Research | ||
| Sandra Patterson, Corporate VP | ||
| Rudolf Ertl, Canada, Australia |
Gilead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gilead Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0056 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 131.81 B | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 88.39 % | ||||
| Revenue | 28.3 B | ||||
| Gross Profit | 21.62 B | ||||
| EBITDA | 13.95 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gilead Stock Analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.